Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents

European Journal of Medicinal Chemistry

Volumn 124, Issue , 2016, Pages 608-621

  Sharma, Pankaj ^a   Srinivasa Reddy, T ^b   Thummuri, Dinesh ^a   Senwar, Kishna Ram ^a   Praveen Kumar, Niggula ^a   Naidu, V G M ^a   Bhargava, Suresh K ^b   Shankaraiah, Nagula ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b RMIT UNIVERSITY   (Australia)

Author keywords

Annexin; Apoptosis; Benzimidazole; Cell migration; MitoSOX; Thiazolidinedione

Indexed keywords

2 (5 ((1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)METHYLENE) 2,4 DIOXOTHIAZOLIDIN 3 YL) N (4 PHENYLTHIAZOL 2 YL)ACETAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ACRIDINE ORANGE; BENZIMIDAZOLE DERIVATIVE; CYTOTOXIC AGENT; ETHIDIUM BROMIDE; F ACTIN; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; LIPOCORTIN 5; PROPIDIUM IODIDE; RHODAMINE 123; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL MIGRATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; DU 145 CELL LINE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; M PHASE CELL CYCLE CHECKPOINT; MCF10A CELL LINE; MDA MB 231 CELL LINE; PC 3 CELL LINE; PROPIDIUM IODIDE ASSAY; A-549 CELL LINE; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

A549 CELLS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NEOPLASMS; THIAZOLIDINEDIONES;

EID: 84986317261     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.08.029     Document Type: Article

References (50)

1. [1] Curran, W.J., New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology 63 (2002), 29–38.
2. [2] Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007), 495–516.
3. [3](a) Fulda, S., Tumor resistance to apoptosis. Int. J. Cancer 124 (2009), 511–515.
4. [3](b) Fulda, S., Debatin, K.-M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006), 4798–4811.
5. [4](a) Fesik, S.W., Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005), 876–885.
6. [4](b) Ghobrial, I.M., Witzig, T.E., Adjei, A.A., Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 (2005), 178–194.
7. [4](c) Fox, J.L., MacFarlane, M., Targeting cell death signalling in cancer: minimising ‘Collateral damage’. Br. J. Cancer 115 (2016), 5–11.
8. [4](d) Senwar, K.R., Reddy, T.S., Thummuri, D., Sharma, P., Naidu, V.G.M., Srinivasulu, G., Shankaraiah, N., Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents. Eur. J. Med. Chem. 118 (2016), 34–46.
9. [4](e) Senwar, K.R., Sharma, P., Reddy, T.S., Jeengar, M.K., Nayak, V.L., Naidu, V.G.M., Kamal, A., Shankaraiah, N., Spirooxindole-derived morpholine-fused-1,2,3-triazoles: design, synthesis, cytotoxicity and apoptosis inducing studies. Eur. J. Med. Chem. 102 (2015), 413–424.
10. [4](f) Kamal, A., Reddy, T.S., Polepalli, S., Paidakula, S., Srinivasulu, V., Reddy, V.G., Jain, N., Shankaraiah, N., Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors. Bioorg. Med. Chem. Lett. 24 (2014), 3356–3360.
11. [5](a) Jain, V.S., Vora, D.K., Ramaa, C.S., Thiazolidine-2,4-diones: progress towards multifarious applications. Bioorg. Med. Chem. 21 (2013), 1599–1620.
12. [5](b) Panigrahy, D., Shen, L.Q., Kieran, M.W., Kaipainen, A., Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Investig. Drugs 12 (2003), 1925–1937.
13. [6](a) Iqbal, A.K.M., Khan, A.Y., Kalashetti, M.B., Belavagi, N.S., Gong, Y.-D., Khazi, I.A.M., Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. Eur. J. Med. Chem. 53 (2012), 308–315.
14. [6](b) Verma, S.K., Thareja, S., Molecular docking assisted 3D-QSAR study of benzylidene-2,4-thiazolidinedione derivatives as PTP-1B inhibitors for the management of type-2 diabetes mellitus. RSC Adv. 6 (2016), 33857–33867.
15. [7](a) Alagawadi, K.R., Alegaon, S.G., Synthesis, characterization and antimicrobial activity evaluation of new 2,4-thiazolidinediones bearing imidazo[2,1-b][1,3,4]thiadiazole moiety. Arab. J. Chem. 4 (2011), 465–472.
16. [7](b) Liu, X.-F., Zheng, C.-J., Sun, L.-P., Liu, X.-K., Piao, H.-R., Synthesis of new chalcone derivatives bearing 2,4-thiazolidinedione and benzoic acid moieties as potential anti-bacterial agents. Eur. J. Med. Chem. 46 (2011), 3469–3473.
17. [8](a) Barros, C.D., Amato, A.A., De Oliveira, T.B., Iannini, K.B.R., da Silva, A.L., da Silva, T.G., Leite, E.S., Hernandes, M.Z., de Lima, M.do C.A., Galdino, S.L., Neves, F.de A.R., Pitta, I.da R., Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands. Bioorg. Med. Chem. 18 (2010), 3805–3811.
18. [8](b) Pomel, V., Klicic, J., Covini, D., Church, D.D., Shaw, J.P., Roulin, K., Burgat-Charvillon, F., Valognes, D., Camps, M., Chabert, C., Gillieron, C., Francüon, B., Perrin, D., Leroy, D., Gretener, D., Nichols, A., Vitte, P.A., Carboni, S., Rommel, C., Schwarz, M.K., Rückle, T., Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49 (2006), 3857–3871.
19. [9](a) Romagnoli, R., Baraldi, P.G., Salvador, M.K., Camacho, M.E., Balzarini, J., Bermejo, J., Estévez, F., Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione. Eur. J. Med. Chem. 63 (2013), 544–557.
20. [9](b) Nagarapu, L., Yadagiri, B., Bantu, R., Kumar, C.G., Pombala, S., Nanubolu, J., Studies on the synthetic and structural aspects of benzosuberones bearing 2,4-thiazolidenone moiety as potential anti-cancer agents. Eur. J. Med. Chem. 71 (2014), 91–97.
21. [9](c) Azizmohammadi, M., Khoobi, M., Ramazani, A., Emami, S., Zarrin, A., Firuzi, O., Miri, R., Shafiee, A., 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur. J. Med. Chem. 59 (2013), 15–22.
22. [9](d) Ramesh, V., Rao, B.A., Sharma, P., Swarna, B., Thummuri, D., Srinivas, K., Naidu, V.G.M., Rao, V.J., Synthesis and biological evaluation of new rhodanine analogues bearing 2-chloroquinoline and benzo[h]quinoline scaffolds as anticancer agents. Eur. J. Med. Chem. 83 (2014), 569–580.
23. [10] Mansure, J.J., Nassim, R., Kassouf, W., Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol. Ther. 8 (2009), 6–15.
24. [11] Knight, S.D., Adams, N.D., Burgess, J.L., Chaudhari, A.M., Darcy, M.G., Donatelli, C.A., Luengo, J.I., Newlander, K.A., Parrish, C.A., Ridgers, L.H., Sarpong, M.A., Schmidt, S.J., Van Aller, G.S., Carson, J.D., Diamond, M.A., Elkins, P.A., Gardiner, C.M., Garver, E., Gilbert, S.A., Gontarek, R.R., Jackson, J.R., Kershner, K.L., Luo, L., Raha, K., Sherk, C.S., Sung, C.-M., Sutton, D., Tummino, P.J., Wegrzyn, R.J., Auger, K.R., Dhanak, D., Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett. 1 (2010), 39–43.
25. [12] Liu, K., Rao, W., Parikh, H., Li, Q., Guo, T.L., Grant, S., Kellogg, G.E., Zhang, S., 3,5-disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. Eur. J. Med. Chem. 47 (2012), 125–136.
26. [13] Jung, K.-Y., Samadani, R., Chauhan, J., Nevels, K., Yap, J.L., Zhang, J., Worlikar, S., Lanning, M.E., Chen, L., Ensey, M., Shukla, S., Salmo, R., Heinzl, G., Gordon, C., Dukes, T., MacKerell, A.D. Jr., Shapiro, P., Fletcher, S., Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signalling. Org. Biomol. Chem. 11 (2013), 3706–3732.
27. [14] Senkiv, J., Finiuk, N., Kaminskyy, D., Havrylyuk, D., Wojtyra, M., Kril, I., Gzella, A., Stoika, R., Lesyk, R., 5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells. Eur. J. Med. Chem. 117 (2016), 33–46.
28. [15] Yadav, G., Ganguly, S., Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: a mini-review. Eur. J. Med. Chem. 97 (2015), 419–443.
29. [16](a) Kim, M.K., Shin, H., Park, K.-S., Kim, H., Park, J., Kim, K., Nam, J., Choo, H., Chong, Y., Benzimidazole derivatives as potent JAK1-selective inhibitors. J. Med. Chem. 58 (2015), 7596–7602.
30. [16](b) Sharma, P., Thummuri, D., Reddy, T.S., Senwar, K.R., Naidu, V.G.M., Srinivasulu, G., Bharghava, S.K., Shankaraiah, N., New (E)-1-alkyl-1H-benzo[d]imidazol-2-yl)methylene)indolin-2-ones: synthesis, in vitro cytotoxicity evaluation and apoptosis inducing studies. Eur. J. Med. Chem. 122 (2016), 584–600.
31. [16](c) Kamal, A., Srinivasulu, V., Sathish, M., Tangella, Y., Nayak, V.L., Rao, M.P.N., Shankaraiah, N., Nagesh, N., Pd-catalyzed aryl C–H activation and tandem ortho-hydroxylation/alkoxylation of 2-aryl benzimidazoles: cytotoxicity and DNA-binding studies. Asian J. Org. Chem. 3 (2014), 68–76.
32. [16](d) Kamal, A., Reddy, T.S., Vishnuvardhan, M.V.P.S., Nimbarte, V.K., Rao, A.V.S., Srinivasulu, V., Shankaraiah, N., Synthesis of 2-aryl-1,2,4-oxadiazolo-benzimidazoles: tubulin polymerization inhibitors and apoptosis inducing agents. Bioorg. Med. Chem. 23 (2015), 4608–4623.
33. [17] Taylor, R.D., MacCoss, M., Lawson, A.D.G., Rings in drugs. J. Med. Chem. 57 (2014), 5845–5859.
34. [18] Meunier, B., Hybrid molecules with a dual mode of action: dream or reality?. Acc. Chem. Res. 41 (2008), 69–77.
35. [19](a) Senwar, K.R., Sharma, P., Nekkanti, S., Sathish, M., Kamal, A., Sridhar, B., Shankaraiah, N., A one-pot ‘click’ reaction from spiro-epoxides catalyzed by Cu(I)-pyrrolidinyl-oxazole-carboxamide. New. J. Chem. 39 (2015), 3973–3981.
36. [19](b) Kamal, A., Srinivasulu, V., Nayak, V.L., Sathish, M., Shankaraiah, N., Bagul, C., Reddy, N.V.S., Rangaraj, N., Nagesh, N., Design and synthesis of C3-pyrazole/chalcone linked β-carboline hybrids: antitopoisomerase I, DNA interactive and apoptosis inducing anticancer agents. ChemMedChem 9 (2014), 2084–2098.
37. [19](c) A. Kamal, K. L. Reddy, V. Devaiah, N. Shankaraiah, G. S. K. Reddy, S. Raghavan, Solid-phase synthesis of a library of pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones with potential antitubercular activity J. Comb. Chem. 9(2007) 29–42.
38. [20] Kar, K., Krithika, U., Mithuna, Basu, P., Kumar, S.S., Reji, A., Kumar, B.R.P., Design, synthesis and glucose uptake activity of some novel glitazones. Bioorg. Chem. 56 (2014), 27–33.
39. [21] Wang, R., Chen, C., Zhang, X., Zhang, C., Zhong, Q., Chen, G., Zhang, Q., Zheng, S., Wang, G., Chen, Q.-H., Structure–activity relationship and pharmacokinetic studies of 1,5-diheteroarylpenta-1,4-dien-3-ones: a class of promising curcumin-based anticancer agents. J. Med. Chem. 58 (2015), 4713–4726.
40. [22] Sharma, P., Senwar, K.R., Jeengar, M.K., Reddy, T.S., Naidu, V.G.M., Kamal, A., Shankaraiah, N., H2O-mediated isatin spiro-epoxide ring opening with NaCN: synthesis of novel 3-tetrazolylmethyl-3-hydroxy-oxindole hybrids and their anticancer evaluation. Eur. J. Med. Chem. 104 (2015), 11–24.
41. [23](a) Liang, C.-C., Park, A.Y., Guan, J.-L., In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2 (2007), 329–333.
42. [23](b) Reddy, T.S., Kulhari, H., Reddy, V.G., Bansal, V., Kamal, A., Shukla, R., Design, synthesis and biological evaluation of 1,3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents. Eur. J. Med. Chem. 101 (2015), 790–805.
43. [24](a) Clainche, C.L., Carlier, M.F., Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol. Rev. 88 (2008), 489–513.
44. [24](b) Reddy, T.S., Reddy, V.G., Kulhari, H., Shukla, R., Kamal, A., Bansal, V., Synthesis of (Z)-1-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(phenylamino)prop-2-en-1-one derivatives as potential anticancer and apoptosis inducing agents. Eur. J. Med. Chem. 117 (2016), 157–166.
45. [25] Chan, K.T., Meng, F.Y., Li, Q., Ho, C.Y., Lam, T.S., To, Y., Lee, W.H., Li, M., Chu, K.H., Toh, M., Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 294 (2010), 118–124.
46. [26] Mallavadhani, U.V., Vanga, N.R., Jeengar, M.K., Naidu, V.G.M., Synthesis of novel ring-A fused hybrids of oleanolic acid with capabilities to arrest cell cycle and induce apoptosis in breast cancer cells. Eur. J. Med. Chem. 74 (2014), 398–404.
47. [27] Barcellona, M.L., Cardiel, G., Gratton, E., Time-resolved fluorescence of DAPI in solution and bound to polydeoxynucleotides. Biochem. Biophys. Res. Commun. 170 (1990), 270–280.
48. [28] Reddy, T.S., Kulhari, H., Reddy, V.G., Rao, A.V.S., Bansal, V., Kamal, A., Shukla, R., Synthesis and biological evaluation of pyrazolo–triazole hybrids as cytotoxic and apoptosis inducing agents. Org. Biomol. Chem. 13 (2015), 10136–10149.
49. [29](a) Hahm, E.-R., Moura, M.B., Kelley, E.E., Houten, B.V., Shiva, S., Singh, S.V., Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One, 6, 2011, e23354.
50. [29](b) Vineetha, V.P., Girija, S., Soumya, R.S., Raghu, K.G., Polyphenol-rich apple (Malus domestica L.) peel extract attenuates arsenic trioxide induced cardiotoxicity in H9c2 cells via its antioxidant activity. Food Funct. 5 (2014), 502–511.